Maze Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · South San Francisco, CA
MAZE chart
What traders are saying about $MAZE
Latest postsMaze Therapeutics, Inc. news
- Maze Therapeutics at Guggenheim conference: enrollment beats guide By Investing.com
Investing.com India ·
- Maze Therapeutics Price Target Raised to $49.00/Share From $48.00 by Wedbush
Moomoo ·
- Wedbush maintains Maze Therapeutics at Outperform, raises price target to $49 from $48
TradingView ·
- Maze Therapeutics Reports Q3 Loss, Highlights Challenges for MAZ
GuruFocus ·
- Maze Therapeutics (MAZE) Misses Q3 EPS by 22c
StreetInsider ·
- Maze Therapeutics completes Phase 2 enrollment for kidney disease drug, expects key data in early 2027
Pluang ·
- Maze Therapeutics Inc Reports Q3 2026 Net Loss of $48 Million, EPS of $0.79 Misses Estimates
GuruFocus ·
- Maze Therapeutics Q3 Results: Loss widens to $0.79 per share
scanx.trade ·
- Maze Therapeutics Q3 results miss estimates on higher R&D spending
TradingView ·
- Maze Therapeutics, Inc. (MAZE) stock price, news, quote and history
Yahoo Finance UK ·
- Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Yahoo Finance ·
- A kidney-disease drug trial finished enrolling more than 50 patients. Results are expected in early 2027.
Stock Titan ·
Maze Therapeutics, Inc. key financials
| USD | 2025 | 2024 |
|---|---|---|
| Revenue | – | $167.5M |
| Net income | -$131.1M | $52.2M |
| Diluted EPS | $-3.05 | $1.25 |
| Total assets (year end) | $397.1M | $240.5M |
| Cash and equivalents (year end) | $189.2M | $196.8M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Maze Therapeutics, Inc.
- Ticker
- MAZE (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- South San Francisco, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1842295
Frequently asked questions
What exchange is Maze Therapeutics, Inc. listed on?
Maze Therapeutics, Inc. trades on the Nasdaq under the ticker symbol MAZE.
What industry is Maze Therapeutics, Inc. in?
Maze Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Maze Therapeutics, Inc. headquartered?
Maze Therapeutics, Inc.'s business address on file with the SEC is in South San Francisco, CA.
When does Maze Therapeutics, Inc.'s fiscal year end?
Maze Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Maze Therapeutics, Inc. report?
Maze Therapeutics, Inc. reported $167.5M in revenue for calendar year 2024, according to its SEC filings.